We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00804206
Recruitment Status : Unknown
Verified December 2008 by Asociación para Evitar la Ceguera en México.
Recruitment status was:  Recruiting
First Posted : December 8, 2008
Last Update Posted : December 8, 2008
Sponsor:
Information provided by:
Asociación para Evitar la Ceguera en México

Brief Summary:
Compare the effect of an intravitreal injection of bevacizumab previous or posterior of panretinal laser photocoagulation (PRLP) with a pattern laser; to prevent and reduce diabetic macular edema (DME) in patients with proliferative diabetic retinopathy (PDR) with DME.

Condition or disease Intervention/treatment Phase
Macular Edema Drug: bevacizumab Phase 4

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation
Study Start Date : July 2008
Estimated Primary Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Group A
Bevacizumab before panretinal photocoagulation.
Drug: bevacizumab
Intravitreal bevacizumab before panretinal photocoagulation
Experimental: Group B
Bevacizumab after panretinal photocoagulation
Drug: bevacizumab
Intravitreal Bevacizumab after panretinal photocoagulation



Primary Outcome Measures :
  1. Central macular thickness [ Time Frame: baseline, 10 days, 52 days, 85 days ]

Secondary Outcome Measures :
  1. Best corrected visual acuity [ Time Frame: baseline, 10 days, 52 days, 85 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with proliferative diabetic retinopathy
  • patients with macular edema

Exclusion Criteria:

  • patients with previous treatments
  • patients with ocular surgeries

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00804206


Contacts
Contact: Miriam Jessica López-Miranda, MD 10841400 ext 1171 jessicalop@hotmail.com

Locations
Mexico
Asociación para Evitar la Ceguera en México Recruiting
México, Mexico, 04030
Contact: Miriam Jessica López-Miranda, MD    10841400 ext 1171    jessicalop@hotmail.com   
Sub-Investigator: Fernando Hernandez-Miranda, MD         
Principal Investigator: Miriam Jessica López-Miranda, MD         
Sub-Investigator: José Luis Guerrero-Naranjo, MD         
Sponsors and Collaborators
Asociación para Evitar la Ceguera en México

Responsible Party: Asociación para evitar la ceguera en mexico, APEC
ClinicalTrials.gov Identifier: NCT00804206     History of Changes
Other Study ID Numbers: APEC-040
First Posted: December 8, 2008    Key Record Dates
Last Update Posted: December 8, 2008
Last Verified: December 2008

Keywords provided by Asociación para Evitar la Ceguera en México:
Intravitreal injection of Bevacizumab
Visual acuity
central retinal thickness
color studies, Farnsworth-Munsell
electroretinogram studies

Additional relevant MeSH terms:
Macular Edema
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents